The Technical Analyst
DURECT Corp [DRRX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
DURECT Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.64% $0.910
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 28.24 mill |
| EPS: | -1.200 |
| P/E: | -0.760 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 31.04 mill |
| Avg Daily Volume: | 0.178 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.760 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.760 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.799 - 1.021 ( +/- 12.20%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-21 | Robertson Judith J. | Buy | 5 500 | Stock Option (right to buy) |
| 2023-06-21 | Maderis Gail J | Buy | 5 500 | Stock Option (right to buy) |
| 2023-06-21 | Garcia Peter S | Buy | 5 500 | Stock Option (right to buy) |
| 2023-06-21 | Farfel Gail M | Buy | 5 500 | Stock Option (right to buy) |
| 2023-06-21 | Blaschke Terrence F | Buy | 5 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 99.20 |
| Last 97 transactions |
| Buy: 5 988 954 | Sell: 1 498 606 |
Forecast:
16:00 - $0.914
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.914
Forecast 2: 16:00 - $0.914
Forecast 3: 16:00 - $0.914
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.910 (3.64% ) |
| Volume | 0.116 mill |
| Avg. Vol. | 0.178 mill |
| % of Avg. Vol | 64.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DRRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DRRX
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Latest Press Releases
2024-03-27 16:01:00 - Press Release
Durect Corporation Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
- ongoing communication with fda to align on next steps for larsucosterol in alcohol-associated hepatitis - webcast of earnings call today, march 27th at 4:30 p.m. et cupertino, calif.
2024-03-20 16:30:00 - Press Release
Durect Corporation To Announce Fourth Quarter And Full Year 2023 Financial Results And Provide A Business Update
Cupertino, calif. , march 20, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on wednesday, march 27, 2024.
2024-03-04 07:00:00 - Press Release
Durect And Charles River Laboratories Enter Into Co-marketing And Collaboration Agreement For Alzet® Product Line In U.s. And Canada
Partnership agreement will be the first-ever co-marketing and sales collaboration for the alzet osmotic pumps portfolio and associated product line in the u.s. and canada both companies will jointly market and commercialize the alzet product line to customers over a multi-year period cupertino, calif. , march 4, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), today announced that it has entered into a co-marketing and collaboration agreement with charles river laboratories for the alzet® osmotic pumps portfolio and associated product line in the u.s. and canada.
2024-02-07 18:48:00 - Press Release
Durect Corporation To Present At The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Cupertino, calif. , feb. 7, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced that james e.
2023-11-13 16:05:00 - Press Release
Durect Corporation Reports Third Quarter 2023 Financial Results And Business Update
- webcast of earnings call today, november 13th at 4:30 p.m. et - topline data from ahfirm trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days cupertino, calif.
Latest News
2024-03-27 18:10:15 - Zacks Investment Research
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.46 per share a year ago.
2023-12-18 07:39:29 - Benzinga
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-11-13 18:50:25 - Seeking Alpha
DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Conference Call Participants François Brisebois - Oppenheimer Carl Byrnes - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Good afternoon, everyone, and welcome to the DURECT Corporation Third Quarter Earnings Conference Call.
2023-11-08 08:40:35 - InvestorPlace
Why Is Durect (DRRX) Stock Down 64% Today?
Durect (NASDAQ: DRRX ) stock is falling hard on Wednesday after the late-stage biopharmaceutical company released results from a Phase 2b clinical trial. This clinical trial covered the efficiency of larsucosterol in treating patients with severe alcohol-associated hepatitis.
2023-10-02 15:07:38 - InvestorPlace
3 Promising Biotech Stocks That Will Make Early Investors Rich
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
2023-08-31 16:30:00 - PRNewsWire
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program , will present in the following September 2023 conferences.
2023-08-09 20:22:07 - Seeking Alpha
DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Timothy Papp - CFO & Secretary James Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Keith Lui - SVP, Business Development, Commercial & Medical Affairs Conference Call Participants Richard Miller - Cantor Fitzgerald Francois Brisebois - Oppenheimer Antonio Arce - H.C. Wainwright & Co. Sean Kim - JonesTrading Operator Greetings, and welcome to the DURECT Corporation Second Quarter Earnings Call.
2023-05-08 22:42:05 - Seeking Alpha
DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Keith Lui - Senior Vice President, Business Development, Commercial, Medical Affairs WeiQi Lin - Executive Vice President, Research and Development, Principal Scientist Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Ed Arce - H.C. Wainwright Francois Brisebois - Oppenheimer Sean Kim - Jones Trading Operator Greetings and welcome to the DURECT Corporation First Quarter 2023 Earnings Call.
2023-05-08 19:02:55 - Zacks Investment Research
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.50 per share a year ago.
2023-05-01 19:03:00 - PRNewsWire
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023.